PARIS--(BUSINESS WIRE)--Regulatory News:
Mauna Kea Technologies (Paris:MKEA) (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today confirmed it is eligible to the PEA-PME investment vehicles, according to decree n° 2014‐283 dated 4 March 2014, ruling on the PEA-PME eligibility criteria for companies.
Investors can continue to place their stocks of Mauna Kea Technologies with their PEA-PME accounts, which are investment vehicles dedicated to small and medium size public and private companies and which provide identical fiscal regime and incentives than the original PME.
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company’s flagship product, Cellvizio, has received clearance to sell a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico.
For more information on Mauna Kea Technologies, visit www.maunakeatech.com